ST. PAUL, Minn.--(BUSINESS WIRE)--Jan. 16, 2008--St. Jude Medical, Inc. (NYSE:STJ) today announced U.S. Food and Drug Administration (FDA) clearance for its EnSite Fusion(TM) Registration Module. The new software will help physicians create detailed heart models to facilitate the diagnosis and delivery of therapy for complex abnormal atrial heart rhythms, including Atrial Fibrillation (AF).
St. Jude Medical's EnSite Fusion software registers, or integrates, an EnSite System-created chamber model with a three-dimensional computed tomography (CT) model so that the physician has an improved view of the heart's anatomy to better guide the delivery of therapy.
St. Jude Medical
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment